View Financial HealthVaxil Bio 배당 및 자사주 매입배당 기준 점검 0/6Vaxil Bio 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-14.2%자사주 매입 수익률총 주주 수익률-14.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 05Vaxil Bio Ltd. announced that it has received CAD 0.14 million in fundingOn December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants.공시 • Dec 04Vaxil Bio Ltd. Announces Board ChangesVaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters.공시 • Oct 30Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in fundingVaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws.공시 • Apr 04Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit CommitteeVaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director).공시 • Jan 17Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025.공시 • Oct 07Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024.공시 • May 28Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.공시 • Mar 06Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024.공시 • Jan 11Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.공시 • Aug 03+ 1 more updateVaxil Bio Ltd. Announces CFO ChangesVaxil Bio Ltd. announced, effective July 31, 2023, in order to reduce costs and preserve cash, Dr. Yuval Avnir, the Company’s CEO will be replaced by Mr. Gadi Levin, the Company’s current chairperson of the board and CFO. The Company further announces, effective July 31, 2023, the appointment of Mr. Alan Rootenberg, as the Company’s CFO. Mr. Rootenberg will be replacing Mr. Gadi Levin, who transitions from the CFO position to the CEO position. Mr. Rootenberg is a chartered professional accountant who has served as the Chief Financial Officer of a number of publicly traded companies listed on the NASDAQ, TSX, TSXV and CSE. These companies include biotechnology, mineral exploration, service technologies and cannabis research companies. He has also served as a director of a number of publicly traded companies. Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.공시 • Jan 05Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOXVAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 VXLL.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: VXLL.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Vaxil Bio 배당 수익률 vs 시장VXLL.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VXLL.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (VXLL.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VXLL.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VXLL.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VXLL.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: VXLL.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 19:22종가2026/05/04 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaxil Bio Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 05Vaxil Bio Ltd. announced that it has received CAD 0.14 million in fundingOn December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants.
공시 • Dec 04Vaxil Bio Ltd. Announces Board ChangesVaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters.
공시 • Oct 30Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in fundingVaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws.
공시 • Apr 04Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit CommitteeVaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director).
공시 • Jan 17Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025.
공시 • Oct 07Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024.
공시 • May 28Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.
공시 • Mar 06Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024.
공시 • Jan 11Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction.Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration. The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.
공시 • Aug 03+ 1 more updateVaxil Bio Ltd. Announces CFO ChangesVaxil Bio Ltd. announced, effective July 31, 2023, in order to reduce costs and preserve cash, Dr. Yuval Avnir, the Company’s CEO will be replaced by Mr. Gadi Levin, the Company’s current chairperson of the board and CFO. The Company further announces, effective July 31, 2023, the appointment of Mr. Alan Rootenberg, as the Company’s CFO. Mr. Rootenberg will be replacing Mr. Gadi Levin, who transitions from the CFO position to the CEO position. Mr. Rootenberg is a chartered professional accountant who has served as the Chief Financial Officer of a number of publicly traded companies listed on the NASDAQ, TSX, TSXV and CSE. These companies include biotechnology, mineral exploration, service technologies and cannabis research companies. He has also served as a director of a number of publicly traded companies. Mr. Rootenberg has a Bachelor of Commerce degree from the University of the Witwatersrand in Johannesburg, South Africa and received his CPA designation in Ontario, Canada.
공시 • Jan 05Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOXVAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales.